Barinthus Biotherapeutics (BRNS) Return on Sales (2020 - 2025)

Barinthus Biotherapeutics has reported Return on Sales for 6 years, with the latest figure at 0.04% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales changed 0.0% year-over-year to 0.04%; the trailing twelve-month figure through Dec 2025 stood at 0.04% (changed 0.0% YoY), and the FY2024 full-year result was 0.04%, up 87.0% from the prior year.
• Return on Sales for Q4 2025 stood at 0.04%, up from 0.05% in the prior quarter.
• The five-year high for Return on Sales was 167.18% in Q4 2021, with the low at 4.82% in Q2 2021.
• Historically, Return on Sales has averaged 9.1% across 5 years, with a median of 0.05% in 2025.
• Annual changes were most pronounced in 2021 — Return on Sales soared 16753 bps — and 2022, when it plunged 16721 bps.
• Barinthus Biotherapeutics' Return on Sales stood at 167.18% in 2021, then tumbled by 100 bps to 0.03% in 2022, then tumbled by 2694 bps to 0.92% in 2023, then jumped by 96 bps to 0.04% in 2024, then declined by 9 bps to 0.04% in 2025.
• The last three Return on Sales figures came in at 0.04% (Q4 2025), 0.05% (Q3 2025), and 0.04% (Q4 2024), per Business Quant data.